Literature DB >> 20380623

Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38.

Alexa Klettner1, Stefan Koinzer, Vicki Waetzig, Thomas Herdegen, Johann Roider.   

Abstract

Deferoxamine mesylate is clinically used as a chelating agent but might induce retinopathy. To evaluate its effect on the retinal pigment epithelium (RPE), porcine RPE cells were stimulated with deferoxamine. Cell death was assessed with trypan blue exclusion assay. To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively. Their activity was determined by Western blot. Deferoxamine induces significant cell death in RPE cells, accompanied by phosphorylation of p38 and Erk. Inhibition of p38 attenuates cell death. In conclusion, deferoxamine is directly toxic on RPE cells, its toxicity depending on p38.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380623     DOI: 10.3109/15569521003745685

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  12 in total

1.  Hyperthermia-induced upregulation of vascular endothelial growth factor in retinal pigment epithelial cells is regulated by mitogen-activated protein kinases.

Authors:  Hendrik Faby; Jost Hillenkamp; Johann Roider; Alexa Klettner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-22       Impact factor: 3.117

2.  Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.

Authors:  Kelly M Bui; SriniVas R Sadda; Hani Salehi-Had
Journal:  Digit J Ophthalmol       Date:  2017-02-13

3.  Nicotine reduces VEGF-secretion and phagocytotic activity in porcine RPE.

Authors:  Alexa Karina Klettner; Johanna Doths; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-21       Impact factor: 3.117

Review 4.  Air pollutants disrupt iron homeostasis to impact oxidant generation, biological effects, and tissue injury.

Authors:  Andrew J Ghio; Joleen M Soukup; Lisa A Dailey; Michael C Madden
Journal:  Free Radic Biol Med       Date:  2020-02-21       Impact factor: 7.376

5.  Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Authors:  Ulrike Baschant; Martina Rauner; Ekaterina Balaian; Heike Weidner; Antonella Roetto; Uwe Platzbecker; Lorenz C Hofbauer
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

6.  Deferoxamine-induced electronegative ERG responses.

Authors:  Ruben Jauregui; Karen Sophia Park; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2018-05-16       Impact factor: 2.379

Review 7.  Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature.

Authors:  Maura Di Nicola; Giulio Barteselli; Laura Dell'Arti; Roberto Ratiglia; Francesco Viola
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

8.  The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism.

Authors:  Paul G Daft; Yang Yang; Dobrawa Napierala; Majd Zayzafoon
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

9.  Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor κB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway.

Authors:  Alexa Klettner; Daniel Westhues; Jens Lassen; Sofia Bartsch; Johann Roider
Journal:  Mol Vis       Date:  2013-01-03       Impact factor: 2.367

10.  Fucoidan reduces secretion and expression of vascular endothelial growth factor in the retinal pigment epithelium and reduces angiogenesis in vitro.

Authors:  Michaela Dithmer; Sabine Fuchs; Yang Shi; Harald Schmidt; Elisabeth Richert; Johann Roider; Alexa Klettner
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.